Prognostic value of plasma endotoxin levels in patients with cirrhosis.
about
Microbial translocation in chronic liver diseasesThe endocannabinoid system as an emerging target of pharmacotherapyMarkers of bacterial translocation in end-stage liver diseaseEvolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Toll-like receptor 4 and hepatic fibrogenesisThe gut microbiome in intestinal fibrosis: environmental protector or provocateur?Urinary metabolite profiling offers potential for differentiation of liver-kidney yin deficiency and dampness-heat internal smoldering syndromes in posthepatitis B cirrhosis patients.Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club.Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection.Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis.LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver diseaseSafety and long-term effect of the probiotic FK-23 in patients with hepatitis C virus infection.Translocation of bacterial NOD2 agonist and its link with inflammation.Toll-like receptors as targets in chronic liver diseases.Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats.Toll-like receptors as therapeutic targets in gastrointestinal diseases.The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A.Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.Toll-like receptor signaling and liver fibrosis.Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitisGut flora and bacterial translocation in chronic liver disease.Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N-acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicity in rats with cirrhosis.Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology?
P2860
Q21284997-1F0F9AC4-BB38-4CB1-9D6E-BAE43EFF39B5Q24648473-E5A407F4-40D6-4D90-96E4-6F1EC069945AQ26783888-D230225C-1648-4DB7-9699-2064B3F4448BQ33755829-3D2515A0-5D1A-4AC6-B1BF-A07DF2E5AE0BQ33905721-C3748A99-403A-41B9-A291-E56DC3B93DAFQ34778411-113008F3-C890-4549-86CA-5732484D1A1DQ35034053-0A290559-6190-4B36-916A-925A62F1C247Q35256601-7A998994-F57C-4DB4-97E6-14E622225896Q35576758-C0C0E112-EE34-4C19-860A-C9C585DCBC5CQ35597315-CF628641-5FD3-42F1-8E6D-CAA4B3D0A558Q35621641-E6E90933-AA2C-42E3-AD24-E2CBAFA22875Q36209740-3E42A553-257D-4783-BFBB-835F7C7EBEB5Q36561514-9924F50A-5005-4F86-85F0-0BC7865B227BQ37136732-B8F0C446-C245-43FB-A061-8A21A811C841Q37360336-E085F2D0-CC84-4CC7-A860-7A00F261E8EEQ37469924-30D2EC69-4900-4BD5-8790-8F23AF7C1BF2Q37596197-3B09991B-F019-43EF-8B02-FF9FBB4D26C8Q37690323-46532592-1BAB-4FBA-B1BA-9BAEAB06492CQ37834316-06B9C4C6-E8C6-494D-B210-4C49E6C25080Q37962297-FCFDC92E-F8B8-42A3-932B-DAC62261AE44Q41350928-755FFE7B-C64F-4517-A08F-9E235FA563CDQ41773351-ED2F4554-FCBA-4776-99C7-487F237B6280Q42132213-0D6E7BF8-DBC2-4858-8251-68BD88D761E9Q42369219-6BFD6B6B-EE3C-4121-8E7E-6424F8A99DD2Q42774107-1F8622AC-7613-445B-A0F3-A5649F5E35B4Q43658822-3154A021-FE60-4874-8E76-9BAD388D3B7EQ44147963-CA590E77-CD16-434A-82C9-AAA250217AFDQ48099354-4E346BF7-DCB9-4BF1-AB1C-20C763D062BEQ49118425-E14CB654-7069-4A01-8904-95682105207EQ55262881-B29ABFA9-48A3-4CF2-9A0F-3E96F5CDE4F3
P2860
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@en
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@nl
type
label
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@en
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@nl
prefLabel
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@en
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@nl
P2093
P1476
Prognostic value of plasma endotoxin levels in patients with cirrhosis.
@en
P2093
P304
P356
10.3109/00365529709011206
P577
1997-09-01T00:00:00Z